The Insurance Shop, Inc. -

Oakland, California-based The Clorox Company (CLX) manufactures and markets consumer and professional products. It operates through Health and Wellness, Household, Lifestyle, and International segments. With a market cap of $15.6 billion, Clorox’s portfolio consists of diverse brands sold in more than 100 countries and nearly every region of the world.

The company is expected to release its Q4 results after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect CLX to report an EPS of $2.24, up an impressive 23.1% from $1.82 reported in the year-ago quarter. While the company has missed Street’s bottom-line estimates once over the past four quarters, it has surpassed the projections on three other occasions.

For the full fiscal 2025, its EPS is expected to come in at $7.08, marking a solid 14.8% growth from $6.17 in fiscal 2024. But in fiscal 2026, its earnings are expected to plunge 8.6% year-over-year to $6.47 per share.

CLX stock prices have dipped 2.4% over the past 52 weeks, notably underperforming the S&P 500 Index’s ($SPX) 13.4% returns and the Consumer Staples Select Sector SPDR Fund’s (XLP) 4.5% uptick during the same time frame.

CLX stock prices dropped 2.4% in the trading session after the release of its disappointing Q3 results on May 5. Due to an unfavorable price mix, the company’s organic sales dropped by 2% year-over-year. Further, its overall sales dropped 8.1% year-over-year to $1.7 billion due to divestitures of the VMS and Argentina businesses. This figure missed consensus estimates by a large margin. Moreover, its adjusted EPS plunged 15.2% year-over-year to $1.45, missing the consensus estimates by 7.6%, breaking its 10 quarters long streak of positive earnings surprises.

CLX stock maintains a consensus “Hold” rating overall, as analysts remain cautious about its prospects. Of the 18 analysts covering the stock, opinions include only one “Strong Buy,” 13 “Holds,” and four “Strong Sell” ratings. As of writing, the stock is trading slightly below its mean price target of $134.69.